Hologic (NASDAQ:HOLX) Raised to Buy at BidaskClub

BidaskClub upgraded shares of Hologic (NASDAQ:HOLX) from a hold rating to a buy rating in a research note published on Friday morning, BidAskClub reports.

Several other research firms have also recently commented on HOLX. Barclays boosted their target price on Hologic from $50.00 to $51.00 and gave the stock an equal weight rating in a research note on Monday, January 13th. William Blair reissued a buy rating on shares of Hologic in a research note on Thursday, November 21st. TheStreet cut Hologic from a b- rating to a c rating in a research note on Wednesday, November 6th. Bank of America raised Hologic from a neutral rating to a buy rating and boosted their target price for the stock from $54.00 to $59.00 in a research note on Thursday, September 26th. Finally, Stifel Nicolaus boosted their target price on Hologic from $48.00 to $52.00 and gave the stock a hold rating in a research note on Friday, December 13th. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating and nine have issued a buy rating to the company’s stock. Hologic currently has an average rating of Buy and an average target price of $55.38.

HOLX stock opened at $54.32 on Friday. The company has a current ratio of 1.68, a quick ratio of 1.26 and a debt-to-equity ratio of 1.32. The company has a market capitalization of $14.57 billion, a PE ratio of -362.13, a P/E/G ratio of 2.39 and a beta of 0.76. Hologic has a 12-month low of $42.61 and a 12-month high of $54.73. The business’s fifty day moving average price is $52.72 and its 200 day moving average price is $49.95.

Hologic (NASDAQ:HOLX) last posted its quarterly earnings data on Wednesday, November 6th. The medical equipment provider reported $0.65 earnings per share (EPS) for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.65. The firm had revenue of $865.80 million for the quarter, compared to the consensus estimate of $846.54 million. Hologic had a positive return on equity of 29.67% and a negative net margin of 1.19%. The company’s quarterly revenue was up 6.4% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.58 EPS. Research analysts predict that Hologic will post 2.62 EPS for the current fiscal year.

In related news, General Counsel John M. Griffin sold 19,624 shares of Hologic stock in a transaction dated Monday, January 13th. The stock was sold at an average price of $52.86, for a total value of $1,037,324.64. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Benjamin Jordan Cohn sold 4,379 shares of Hologic stock in a transaction dated Wednesday, December 4th. The stock was sold at an average price of $52.74, for a total value of $230,948.46. Insiders sold 251,453 shares of company stock valued at $11,871,295 over the last quarter. Insiders own 0.90% of the company’s stock.

Large investors have recently bought and sold shares of the stock. Horan Capital Advisors LLC. bought a new stake in Hologic during the third quarter worth approximately $34,000. CSat Investment Advisory L.P. grew its position in Hologic by 66.9% during the 2nd quarter. CSat Investment Advisory L.P. now owns 831 shares of the medical equipment provider’s stock worth $40,000 after purchasing an additional 333 shares in the last quarter. North Star Investment Management Corp. purchased a new position in Hologic during the 3rd quarter worth approximately $80,000. KCS Wealth Advisory purchased a new position in Hologic during the 3rd quarter worth approximately $89,000. Finally, Private Capital Group LLC grew its position in Hologic by 62.2% during the 2nd quarter. Private Capital Group LLC now owns 2,327 shares of the medical equipment provider’s stock worth $92,000 after purchasing an additional 892 shares in the last quarter. Institutional investors and hedge funds own 94.08% of the company’s stock.

About Hologic

Hologic, Inc, a medical technology company, develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women in the United States, Europe, the Asia-Pacific, and internationally. It operates in five segments: Diagnostics, Breast Health, Medical Aesthetics, GYN Surgical, and Skeletal Health.

Recommended Story: Range Trading

Analyst Recommendations for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.